Connect with us

General Other

Read This Before Considering Broadcom Inc. (NASDAQ:AVGO) For Its Upcoming US$3.25 Dividend

mm

Published

on

Yahoo Finance

TipRanks

Oppenheimer: 3 Stocks That Could Surge Over 100% From Current Levels

So far, September has been a wild ride of ups and downs. Following the recent bout of volatility, stocks have ticked higher again. But as uncertainty regarding another rescue program and the presidential election continues to linger, where does the market go from here? Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus argues that any market dips appear “relatively contained and orderly,” and present longer-term investors the chance to find “babies that got thrown out with the bathwater.” He noted, “For nervous investors the recent downdraft has presented opportunity to take some profits without FOMO (fear of missing out).”As for the tech heavyweights that powered the market’s five-month charge forward, the strategist believes “current expectations that technology stocks will remain under pressure for some time seem exaggerated.” Stoltzfus adds that the “core of technology stocks did not appear terribly rich in price considering that developments in technology and innovation have yet to show signs of plateauing in the current cycle.”Taking Stoltzfus’ outlook into consideration, our focus turned to stocks that Oppenheimer analysts are bullish on. The firm’s pros see triple-digit upside potential in store for three tickers in particular. Running the names through TipRanks’ database, we wanted to find out what makes each so compelling.MediWound Ltd. (MDWD)Developing cutting-edge products, MediWound wants to address unmet needs in the fields of severe burn and chronic wound management. With an important government contract secured, Oppenheimer has high hopes for this name.Back in January, MDWD announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) had entered into a contract to procure $16.5 million of NexoBrid, its drug designed to remove eschar in adults with deep partial and full-thickness thermal burns (a process called debridement), for an emergency stockpile. According to management, the first delivery is set for Q3 2020.On top of this, the company filed the NexoBrid Biologics License Application (BLA) with the FDA for eschar removal in adults with deep partial-thickness and full-thickness thermal burns in June. MDWD’s U.S. commercial partner, Vericel, is preparing for an immediate launch upon approval.Representing Oppenheimer, 5-star analyst Kevin DeGeeter points out that “Given the filing involved participation from three parties—MDWD, U.S. commercial partner Vericel and funding partners at BARDA—and was completed against the backdrop of public sector work-from-home mandates, we view meeting stated timelines as a material milestone and derisking event for MDWD shares… we believe NexoBrid is on track for 1H21 launch.”Should the therapy ultimately be approved, MDWD is entitled to a $7.5 million milestone payment from Vericel. “We believe the combination of existing cash and the $7.5 million milestone payment from VCEL upon NexoBrid approval should fund operations at least into 2H23,” DeGeeter added.DeGeeter also points out that MDWD plans to open 25-30 sites in U.S. and Israel to support the Phase 2 study of EscharEx, its product for chronic wounds. Although COVID-19 resulted in a delay, the analyst thinks “the current timeline of 1H21 is achievable.”To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards. (To watch DeGeeter’s track record, click here)All in all, other analysts echo DeGeeter’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. With an average price target of $6.63, the upside potential comes in at 106%. (See MDWD stock analysis on TipRanks)UroGen Pharma (URGN)Primarily focused on uro-oncology, UroGen Pharma develops advanced non-surgical treatments to improve the lives of patients. As the launch of one of its products is progressing well, Oppenheimer thinks that now is the time to get on board.Writing for the firm, analyst Leland Gershell points to UGN-101 as a key component of his bullish thesis. UGN-101, which has now been formally launched in the U.S. under the commercial name Jelmyto, was designed as a treatment for low-grade upper tract urothelial carcinoma (LG UTUC). The analyst highlights that Jelmyto’s launch is already off to a solid start, as eight patients had received 20 doses of the drug in June.“Jelmyto sales were $371,000 in its first month of launch, but more important was management’s commentary that over 100 urology practice sites are treatment-ready for the product, and that patient demand has not been visibly impacted by COVID-19,” Gershell explained.Adding to the good news, permanent C- and J-codes, which are expected in October and January 2021, respectively, could bolster sales, in Gershell’s opinion. The label could also be updated to reflect completed OLYMPUS data.It should be noted that patient and physician engagement could remain diminished through YE20, and restrictions around elective surgeries could persist, according to Gershell. That said, he argues that “LG UTUC’s lack of surgical urgency could imply treatment deferral for several months, whereas Jelmyto’s ability to be administered in an outpatient setting could expedite treatment, favoring adoption.”If that wasn’t enough, UGN-102, its mitomycin gel that targets low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC), is set to enter pivotal testing before the end of 2020. Looking at previously released data, the therapy achieved a 65% complete response (CR) rate at three months following onset of treatment. “To offset any potential COVID-19 impact on enrollment, URGN has increased the number of clinical trial sites outside of the U.S., in those countries where virus-related clinical delays have not cropped up,”Gershell added.Summing it all up, Gershell commented, “We believe shares trade at a discount to the value of Jelmyto and UGN-102, and that revenue growth will support stock upside over the next 12 months.”To this end, Gershell stands with the bulls, reiterating an Outperform rating. At $48, his price target brings the upside potential to 123%. (To watch Gershell’s track record, click here)What does the rest of the Street have to say? 3 Buy ratings and 1 Hold have been issued in the last three months. As a result, URGN receives a Strong Buy consensus rating. In addition, the $44 average price target suggests 104% upside potential. (See URGN stock analysis on TipRanks)Ayala Pharmaceuticals Inc. (AYLA)Last but not least we have Ayala Pharmaceuticals, which is focused on developing targeted therapies for cancers in which Notch activation is a known tumor driver. Based on the progress across its development pipeline, Oppenheimer sees big gains in store.Oppenheimer analyst Jay Olson thinks AYLA’s technology makes it a stand-out. Its two candidates, AL101 and AL102, which are in-licensed from Bristol Myers, are gamma-secretase inhibitors that target aberrant activation of Notch signaling in cancer cells.Notch signaling plays an important role in normal cell development, and perturbations can cause malignant transformation. “We believe Notch targeted therapies hold promise in addressing unmet clinical needs,” Olson commented.The analyst added, “The Notch mutational landscape is diverse, and the underlying science is evolving. AYLA is building a bioinformatics database around Notch to better characterize and identify Notch-activating mutations. Additionally, AYLA is collaborating with partners developing diagnostic tests for Notch-activating mutations, both at DNA and RNA levels. We believe these initiatives benefit AYLA in the long term by identifying responders and expanding the addressable patient population.”Despite the challenges presented by COVID-19, critical catalysts remain on track. The company is set to present new interim data from the Phase 2 ACCURACY open-label study of AL101 in R/M ACC at the mini oral head and neck cancer section of ESMO. Looking at the available data, a recent interim analysis in one cohort showed 69% DCR.As for the second cohort, it is evaluating a 6mg once-weekly dosing of AL101. “We view the efficacy and safety data from the 6mg dosing cohort as important for the registration-enabling studies, and we anticipate similar interim data readout in 1H21,” Olson said.Adding to the good news, AYLA is on track to kick off patient dosing in the Phase 2 TENACITY study of AL101 in R/M TNBC by YE20 after the IND was cleared by the FDA in April. In 2021, AYLA plans to initiate two additional Phase 2 studies including AL102 for desmoid tumors and AL101 for r/r T-ALL.“Springworks Therapeutics recently announced the completion of patient enrollment of the Phase 3 DeFi trial of nirogacestat in desmoid tumors with topline data expected mid-2021, which should provide read-across to AYLA’s AL102 program,” Olson noted.Given all of the above, Olson opined, “We’re encouraged by AYLA’s advantages along several dimensions, including its drug candidates, cancer indication selection, and focus on identifying Notch-activating mutations while developing diagnostics. AYLA’s Notch targeted approach should address unmet clinical needs for patients with rare but aggressive cancers.”It should come as no surprise, then, that Olson stayed with the bulls. To this end, he kept an Outperform rating and $23 price target on the stock, implying 123% upside potential. (To watch Olson’s track record, click here)Looking at the consensus breakdown, 2 Buys and 1 Hold have been published in the last three months. Therefore, AYLA gets a Moderate Buy consensus rating. Based on the $19.83 average price target, shares could climb 92% higher in the next year. (See AYLA stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

General Other

New poll shows Lindsey Graham, Jaime Harrison tied in South Carolina

mm

Published

on

New poll shows Lindsey Graham, Jaime Harrison tied in South Carolina

A new Quinnipiac University poll released on Wednesday shows Sen. Lindsey Graham (R-S.C.) and Jaime Harrison, his Democratic challenger, tied at 48 percent among likely voters.

The survey also found that 48 percent of voters see Harrison in a favorable light compared to 43 percent who have a favorable opinion of Graham, and 51 percent of voters have an unfavorable view of Graham, compared to 35 percent who hold an unfavorable view of Harrison. Harrison is outspending Graham on advertisements and also bringing in more money from grassroots supporters, and Graham in turn has been making regular appearances on Fox News, asking viewers for money.

The race is also tight in the state between President Trump and Democratic presidential nominee Joe Biden, with Trump leading Biden by 1 percentage point, 48 to 47 percent. Trump won South Carolina by about 14 points in 2016, with 54.9 percent of the vote.

The survey was conducted from Sept. 23 to 27, with 1,123 likely voters polled. The margin of error is plus or minus 2.9 percentage points.

More stories from theweek.com
Trump keeps claiming Biden, who has recommitted to the next 2 debates, wants to cancel the debates
Italian couple set to wed after falling in love from their balconies
Marvel casts newcomer in the role of its 1st Muslim superhero, Ms. Marvel

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Three times Trump was racist during presidential debate

mm

Published

on

Three times Trump was racist during presidential debate
President Donald Trump again on Wednesday would not denounce white supremacist groups. ((REUTERS))

President Donald Trump was called racist by Democratic nominee Joe Biden during the first presidential debate, as the Republican candidate repeatedly used racist tropes to defend his supporters and engage in personal attacks.

During Tuesday’s debate, which was the first of the three scheduled before 3 November’s election, Mr Trump repeatedly interrupted and spoke over Mr Biden, as he launched attacks on the former vice president and other Democratic officials.

During a discussion about racial sensitivity training, Mr Biden called the president racist over his decision to ban the practice for federal contractors earlier in the year.

Mr Biden, who has undertaken the training, claimed: “This is a president who has used everything as a dog whistle to try to generate racist hatred, racist division.”

Mr Biden added later on in the debate, while the candidates clashed over Black Lives Matter protests: “He’s the racist.”

However, there were other moments during the debate where the president used racist tropes – while talking about the coronavirus pandemic, white supremacists and senator Elizabeth Warren.

The president refused to condemn white supremacist groups

On Tuesday, the president refused to condemn the violence of far-right and white supremacist groups during Black Lives Matter protests this summer, when moderator Chris Wallace, of Fox News, repeatedly asked him to.

Mr Trump initially tried to avoid the question by asking Mr Wallace for a specific group that he wanted him to condemn, but eventually chose to address the far-right, white supremacist group, the Proud Boys.

He said: “Proud Boys, stand back and stand by! But I’ll tell you what, somebody’s got to do something about antifa and the left.”

In reaction to the president’s comments, a key Proud Boys organiser wrote on the “free speech” social network, Parler: “Standing by sir.”

Following the debate, experts warned that Mr Trump’s comment could encourage violence from extremist groups.

Kathleen Belew, a historian of American white power movements, tweeted: “A green light like ‘stand back and standby’ is catastrophic.”

Jonathan Greenblatt, the CEO of the Anti-Defamation League (ADL), also tweeted his concern, and said that the president “owes America an apology or an explanation. Now,” for his comments.

President Trump called senator Elizabeth Warren ‘Pocahontas’

During the debate, Mr Trump questioned whether Mr Biden would have won the Democratic nomination if senator Elizabeth Warren had not dropped out of the race, and called her “Pocahontas” while doing so.

He said: “If Pocahontas would have left [the race] two days earlier, you would’ve lost every primary on Super Tuesday,” in reference to the senator’s previous claims that she has Native American heritage.

Pocahontas was a Native American woman, who belonged to the Pamunkey tribe. She was born in 1596 and died in 1617.

In 2018, president Trump claimed that Ms Warren was lying about her Cherokee heritage for political gain, and in response the senator took a DNA test, which showed that she was between 1/64th and 1/1028th Native American. She subsequently apologised for her previous claims.

However, Mr Trump has continued to refer to Ms Warren as Pocahontas, and although it was not commented on during the debate, the president using the term has caused upset to Native American people in the US.

In 2019, the National Congress of American Indians (NCAI), which describes itself as the oldest and largest indigenous rights organisation in the US, said the president’s actions were part of a long tradition of insults endured by Native Americans.

“For centuries Native people have endured such slurs – from ‘R*dskins’ to ‘Injuns’ to ‘savages’ – that the forces of racism and intolerance deploy to dehumanise our people, mock our cultures, and interfere with our inherent right to control our own lands and destinies,” said NCAI CEO Kevin Allis.

He added: “Not only does it disrespect Pocahontas’ legacy and life, it likens her name to a slur.”

The president once again called coronavirus the ‘China plague’

During the debate, the president once again referred to the coronavirus pandemic as the “China plague,” while defending his administration’s response to tackling the virus.

He said: “We built the greatest economy in history, we closed it down because of the China plague.”

According to a tracking project hosted by Johns Hopkins University, in the US as a whole, some 7.1 million people have tested positive for coronavirus, while the death toll has reached at least 206,351.

Mr Trump, alongside other Republicans, has repeatedly referred to Covid-19 as the “China virus,” or “Wuhan flu,” and other slurs during the pandemic, which have been criticised for blaming the virus on a single country and group of people.

Additionally, there are concerns that the phrase could lead to a rise of harassment and mistreatment of Asian Americans, according to NBC News.

Speaking at a virtual invitation-only fundraiser for Joe Biden‘s presidential campaign last month, the former US president Barack Obama criticised Mr Trump’s use of the phrase, according to The Hill.

“I don’t want a country in which the president of the United States is actively trying to promote anti-Asian sentiment and thinks it’s funny,” Mr Obama reportedly said.

“I don’t want that. That still shocks and p***es me off,” he added.

Earlier in the year, the World Health Organisation (WHO) director general, Tedros Adhanom, said the name specifically does “not refer to a geographical location, an animal, an individual or group of people, and which is also pronounceable and related to the disease,” according to Forbes.

He reasoned that “having a name matters to prevent the use of other names that can be inaccurate or stigmatizing”.

The second presidential debate is scheduled to take place on 15 October in Miami with C-SPAN’s Steve Scully moderating.

Read more

‘This is a colossal waste of time’: Pundits and Biden supporters call for him to drop out of remaining debates

‘Painful to watch’: Body language expert explains the first Trump-Biden debate

Biden, Trump press contrasts in Midwest after debate chaos

The Proud Boys heard Trump last night. Their reaction tells you everything you need to know

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

General Other

Fiery interview between Ted Cruz and Chris Cuomo turns personal: 'Why don't you talk to the president like you talk to my brother?'

mm

Published

on

Fiery interview between Ted Cruz and Chris Cuomo turns personal: 'Why don't you talk to the president like you talk to my brother?'

Ted Cruz and Chris Cuomo took part in a contentious interview during ‘Cuomo Prime Time’ on Wednesday night.

mm

Christine founded Sports Grind Entertainment with an aim to bring relevant and unaltered Sports news to the general public with a specific view point for each story catered by the team. She is a proficient journalist who holds a reputable portfolio with proficiency in content analysis and research.

Continue Reading

Trending